Mesoblast reports 44% revenue surge in Ryoncil sales for Q1 FY26

Mesoblast Ryoncil biotechnology cellular medicine quarterly earnings

Mesoblast Limited, a Melbourne-based biotechnology firm specializing in allogeneic cellular medicines, reported strong financial results for its first fiscal quarter ending September 30, 2026.

The company announced a 44% increase in net revenue from its Ryoncil product, reaching US$28 million, up from US$19 million in the same period last year. Additionally, Mesoblast achieved an 85% improvement in net operating cash spend, which fell to US$2.3 million from US$14.9 million in the prior year.

Ryoncil, which is FDA-approved for children under 12 with steroid-refractory acute graft-versus-host disease, saw its highest number of new patient starts in September. The company reported a total cash position of US$99 million and plans to continue expanding Ryoncil adoption across its 54 onboarded treatment sites.

Entities

Melbourne · Mesoblast Limited · Ryoncil · Silviu Itescu · U.S. Food and Drug Administration

Claims

What the coverage asserts, and how many sources carry each claim.

[● 3 SOURCES] Net operating cash spend improved by 85%, reducing to US$2.3 million from US$14.9 million in the prior year period. www.finnewsnetwork.com.au · www.sharecafe.com.au · www.fool.com.au
[● 3 SOURCES] Mesoblast reported its first fiscal quarter results for the period ending September 30, 2026. www.finnewsnetwork.com.au · www.sharecafe.com.au · www.fool.com.au
[● 3 SOURCES] Net revenue from Ryoncil sales increased 44% to US$28 million compared to US$19 million in the prior year period. www.finnewsnetwork.com.au · www.sharecafe.com.au · www.fool.com.au
[● 3 SOURCES] The company recorded a cash position of US$99 million as of September 30, 2026. www.finnewsnetwork.com.au · www.sharecafe.com.au · www.fool.com.au
[● 3 SOURCES] Ryoncil adoption is occurring across 54 onboarded treatment sites. www.finnewsnetwork.com.au · www.sharecafe.com.au · www.fool.com.au
[● 3 SOURCES] Ryoncil is the only FDA-approved mesenchymal stromal cell product for children under age 12 with steroid-refractory acute graft-versus-host disease. www.finnewsnetwork.com.au · www.sharecafe.com.au · www.fool.com.au

Sources

Mesoblast Reports Strong Q1 FY26 with Soaring Ryoncil® Revenue and Improved Cash Position [www.finnewsnetwork.com.au]

11 days ago

Mesoblast Reports Strong Q1 FY26 with Soaring Ryoncil® Revenue and Improved Cash Position [www.sharecafe.com.au]

11 days ago

Mesoblast reports Ryoncil revenue surge and improved cash spend [www.fool.com.au]

11 days ago